The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
Granulocyte-colony stimulating factor (G-CSF) is konwn to have no significant effect on
leukemia stem cells and has been widely used in the patients with agranulocytosis after
chemotherapy. Minimal residual disease (MRD), an index for early treatment response, plays an
important role in prognostic prediction. Numbers of data have shown MRD at day 14 after
induction therapy significantly predicts prognosis. However, the retrospetive data from the
investigators showed that patients with G-CSF treatment after induction had higher MRD at day
14 but not significantly different at day 28, suggesting that G-CSF might work on the
differenciation of hemapoetic stem cells and increase MRD levels at day 14. In this
multicenter prospective randomized controlled study, the effect of G-CSF on MRD after
induction therapy in newly diagnosed acute myeloid leukemia (AML) is evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Guangzhou First People's Hospital Peking University Shenzhen Hospital Second Affiliated Hospital, Sun Yat-Sen University Shenzhen Hospital of Southern Medical University